Amarantus Bioscience - AMBS - Get In Today For Less than A Dime
The company’s C.E.O. is holding a conference call on April 16.
During the conference call I'm certain that Gerald will clarify the expected time frame for the commercial launch of each of the tests.
Many individuals confuse the testing process and time frames for the trials that a drug must undergo to obtain F.D.A. approval when referencing the stages as it relates to a diagnostic test being evaluated and approved. As Gerald has stated the time to approval is significantly shorter for a test for a disease that has no known cure which is applicable with Lympro and Nuropro.
I think this is an important point that many posters on the board have missed.
Amarantus Diagnostics could be generating $300,000,000 in annual revenues within two years.
The point being that the current share price substantially undervalues the company's potential.
I think the share price should be in the .40 range currently. I'm expecting it to be above .15 by the time of the conference call on April 16 and .25 at the open on April 17 and moving up from there.
A partnership announcement will move the share price above .35 overnight.
Each of the new board members have over 500 connections on Linkedin. Please note who were some of the recent viewers of their profiles.
Each is a potential new shareholder. The word is getting out to the market.
There are some very prominent individuals viewing their profiles. Take the time to view these individual's profiles. I would bet they're within six degrees of every C.E.O. of every major drug company in the world.
Dr. Adam J. Simon
• Jim Ray
Senior Director at Envoy Therapeutics,...
• Joseph Vacca
Head of Early Success Sharing...
• David Devilbiss
Founder of NexStepBiomarkers, LLC.
• Paul Shughrue
Research at Prothena Biosciences
• Mary J. Savage
Scientific Director at Merck and Company
• Sethu Sankaranarayanan
Scientist at Bristol-Myers Squibb
• Jeffrey Vivian
• Peter Como
Neuropsychologist at Food and Drug...
• Annie Liang
Research Biologist at Merck
p.s. Dr. Benedyk and Dr. Simon are two important pieces of the puzzle.